Ipamorelin + CJC-1295 (No DAC) — Synergistic Growth Hormone Secretagogue Research Peptide Combination | Klene Peptides
For Research Use Only | Not for Human or Veterinary Administration
Ipamorelin and CJC-1295 without DAC represent two mechanistically distinct growth hormone (GH) secretagogues that, when combined in research protocols, produce synergistic amplification of pulsatile GH release through simultaneous engagement of separate receptor pathways. Ipamorelin acts as a selective agonist at the ghrelin/GH secretagogue receptor (GHSR-1a), while CJC-1295 without DAC — also known as Modified GRF(1-29) — stimulates the pituitary growth hormone-releasing hormone receptor (GHRHR). Together, their combined signal closely replicates the natural GH pulse architecture generated by coordinated GHRH-ghrelin axis activity, making this combination one of the most studied in GH pulse amplification and neuroendocrine research. Klene Peptides supplies this combination to USA research institutions with verified purity and same-day fulfillment.
Every vial from Klene Peptides includes:
- ≥99%+ purity — verified by HPLC (High-Performance Liquid Chromatography)
- HPLC-MS (High-Performance Liquid Chromatography - Mass Spectrometry)
- Same-day shipping for all USA orders
Chemical Identity & Structural Profiles
Ipamorelin
| Parameter | Value |
|---|---|
| Full Name | Ipamorelin |
| Sequence | H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Residue Class | Growth Hormone Releasing Peptide (GHRP); pentapeptide |
| Molecular Weight | 711.86 g/mol |
| CAS Number | 170851-70-4 |
| Primary Target | GHSR-1a (Ghrelin / GH Secretagogue Receptor 1a) |
| Appearance | White lyophilized powder |
| Storage | Lyophilized: −20°C; Reconstituted: 4°C, use within 14–21 days |
CJC-1295 Without DAC (Modified GRF 1-29)
| Parameter | Value |
|---|---|
| Full Name | CJC-1295 without DAC / Modified GRF(1-29) / Mod-GRF(1-29) |
| Sequence | 29-amino acid GHRH(1-29) analog with stabilizing substitutions |
| Key Substitutions | Enhanced DPP-IV resistance at positions 2, 8, 15, 27 |
| Molecular Weight | ~3,367 g/mol |
| CAS Number | 863288-34-0 |
| Primary Target | GHRHR (Growth Hormone-Releasing Hormone Receptor) |
| Appearance | White lyophilized powder |
| Storage | Lyophilized: −20°C; Reconstituted: 4°C, use within 14–21 days |
Key distinction: CJC-1295 with DAC (Drug Affinity Complex) uses a reactive maleimide group to form a covalent bond with serum albumin, extending its half-life to 6–8 days. CJC-1295 without DAC lacks this conjugation, producing a shorter half-life (~30 minutes) that mimics the natural GHRH pulse — the preferred form for pulsatile GH physiology research.
Mechanism of Action
Dual-Receptor Synergy
| Component | Receptor | Signal | Effect |
|---|---|---|---|
| Ipamorelin | GHSR-1a (ghrelin receptor) | Gq/11 → PKC; Gi/o → cAMP reduction | Selective GH pulse release; no significant cortisol or prolactin elevation |
| CJC-1295 No DAC | GHRH receptor | Gs → adenylate cyclase → cAMP → PKA | GH synthesis upregulation; somatotroph cell sensitization |
| Combined | Both GHSR-1a + GHRHR | Additive/synergistic intracellular signals | Amplified, physiologically-patterned GH pulse |
The synergy is mechanistically important: CJC-1295 no DAC stimulates the synthesis and priming of GH in somatotroph cells via the cAMP/PKA pathway, while Ipamorelin simultaneously triggers GH release through the ghrelin receptor’s calcium-dependent exocytosis pathway. The result is a GH pulse of greater amplitude than either peptide alone, without suppressing the hypothalamic-pituitary axis feedback loop.
Selectivity Profile of Ipamorelin
| Hormone / Parameter | Effect | Research Significance |
|---|---|---|
| Growth Hormone (GH) | Significant elevation | Primary endpoint in GH pulse research |
| IGF-1 | Secondary increase (GH-mediated) | Tissue anabolic signaling studies |
| Cortisol | No significant increase | Distinguishes Ipamorelin from GHRP-2 and GHRP-6 |
| Prolactin | No significant increase | High selectivity advantage in neuroendocrine research |
| ACTH | No significant increase | HPA axis neutrality confirmed |
| Appetite / Ghrelin Effects | Minimal at research doses | Functionally distinct from endogenous ghrelin |
Pharmacokinetic & ADME Profiles
Ipamorelin
| Parameter | Value | Notes |
|---|---|---|
| Route (Research) | SC, IV | SC preferred for pulsatile studies |
| Tmax | ~15–30 minutes (SC) | Rapid peak GH elevation |
| Half-life (t½) | ~2 hours | Short-acting; designed for pulsatile stimulation |
| Bioavailability (SC) | >70% (estimated) | High subcutaneous absorption |
| Metabolism | Proteolytic (serum and tissue) | No CYP450 pathway |
| Excretion | Renal | Metabolite clearance |
CJC-1295 No DAC
| Parameter | Value | Notes |
|---|---|---|
| Route (Research) | SC | Standard research delivery |
| Tmax | ~5–15 minutes (SC) | Rapid receptor engagement |
| Half-life (t½) | ~30 minutes | Without albumin conjugation; pulse-appropriate |
| Bioavailability (SC) | >75% (estimated) | High subcutaneous absorption |
| Metabolism | DPP-IV resistant vs. native GHRH; proteolytic | Modified sequence resists rapid DPP-IV cleavage at Ala² |
| Excretion | Renal | Metabolite clearance |
Research Applications
GH Pulse Architecture Research
| Research Parameter | Methodology | Observed Outcome |
|---|---|---|
| GH Peak Amplitude | Serial serum GH measurement post-administration | 2–5× baseline GH elevation vs. either peptide alone |
| Pulse Duration | AUC analysis over 2–4 hour windows | Extended pulse profile vs. Ipamorelin alone |
| IGF-1 Response | 24-hour serum IGF-1 measurement | Dose-dependent sustained elevation |
| HPA Axis Neutrality | ACTH and cortisol co-measurement | No significant HPA perturbation |
Body Composition & Metabolic Research
| Area | Mechanism | Research Focus |
|---|---|---|
| Lean Mass | GH/IGF-1 anabolic signaling | Muscle protein synthesis rate studies |
| Adipose Reduction | GH-driven lipolysis (visceral and subcutaneous) | Fat mass and body composition modeling |
| Glucose Metabolism | GH-mediated insulin sensitivity modulation | Metabolic flexibility and HOMA-IR studies |
Aging & Somatopause Research
GH secretion declines approximately 1–2% annually after peak in early adulthood (somatopause). This combination is studied to:
- Model restoration of youthful GH secretion patterns
- Investigate downstream effects of recovered GH/IGF-1 on age-associated tissue changes
- Characterize sleep-associated GH pulse restoration and quality-of-sleep metrics
Sleep & Circadian Biology
GH secretion is primarily nocturnal and linked to slow-wave sleep. Research protocols examine how GH secretagogue combinations affect:
- Nocturnal GH pulse amplitude and frequency
- REM and slow-wave sleep architecture parameters
- Next-morning IGF-1 levels as surrogate endpoints
Research Dosing Reference
For scientific reference only — not prescriptive recommendations
| Peptide | Reported Dose Range | Route | Timing |
|---|---|---|---|
| Ipamorelin | 100–300 mcg per administration | SC | Pre-sleep or fasted state |
| CJC-1295 No DAC | 100–300 mcg per administration | SC | Co-administered with Ipamorelin |
| Combined (typical research) | 100–200 mcg each, combined per injection | SC | 1–3× daily per protocol design |
Dosing ranges derived from published pharmacological and clinical research literature.
Reconstitution Reference
| Lyophilized Amount (each peptide) | Bacteriostatic Water | Concentration |
|---|---|---|
| 5 mg | 2.5 mL | 2.0 mg/mL |
| 10 mg | 5.0 mL | 2.0 mg/mL |
Klene Peptides Quality Standards
Certificate of Analysis — Standard Parameters
Every batch supplied by Klene Peptides is verified against the following analytical benchmarks:
| Test | Specification | Method |
|---|---|---|
| Purity (both components) | ≥99% | HPLC (High-Performance Liquid Chromatography) |
| Molecular Identification | Confirmed for each component | HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry) |
| Water Content | <1.5% | — |
What Every Klene Peptides Order Includes
- Lot-specific Certificate of Analysis traceable to synthesis batch
- Verified cold-chain shipping — all orders dispatched with appropriate cold-pack packaging
- Same-day fulfillment — orders placed before cutoff ship the same business day
Ordering Ipamorelin + CJC-1295 (No DAC) for Your Research Program
Important Research Compliance Notice
All products sold by Klene Peptides are strictly for in vitro research and laboratory investigation purposes only. Ipamorelin and CJC-1295 (No DAC) supplied by KlenePeptides.net have not been evaluated by the FDA for human safety or efficacy. They are not approved for human or veterinary administration. Purchase, possession, and use must comply with all applicable federal, state, and local regulations. This content is intended for licensed researchers and qualified scientific personnel only.
Scientific References
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561.
- Teichman SL, et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805.
- Bowers CY, et al. "Growth hormone releasing peptides and their analogues." Front Neuroendocrinol. 1993.
- Müller EE, et al. "Neuroendocrine control of growth hormone secretion." Physiol Rev. 1999;79(2):511-607.
- Kojima M, et al. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature. 1999;402(6762):656-660.
- PubChem. Ipamorelin. CID: 9831659. https://pubchem.ncbi.nlm.nih.gov
- PubChem. CJC-1295. CID: 56841945. https://pubchem.ncbi.nlm.nih.gov